Enovis (NYSE:ENOV) Stock Price Target Lowered at Canaccord Genuity Group

Key Points

• Canaccord lowered its Enovis price target from $45 to $42 but maintained a Buy rating; the new target implies 53.83% upside from the prior close.
• Analyst sentiment remains broadly positive: MarketBeat reports a consensus Moderate Buy rating and an average price target of $38.62.
• Enovis beat quarterly estimates, reporting EPS of $0.88 versus $0.77 expected and revenue of $558.7 million, up 1.8% year over year. Company insiders also purchased 23,293 shares worth about $449,600 over the prior 90 days.

Enovis (NYSE:ENOV - Get Free Report) had its target price reduced by equities research analysts at Canaccord Genuity Group from $45.00 to $42.00 in a report issued on Friday, Benzinga reports. The firm currently has a "buy" rating on the stock. Canaccord Genuity Group's price target indicates a potential upside of 53.83% from the stock's previous close.

A number of other research analysts have also issued reports on the stock. UBS Group reissued a "buy" rating and set a $44.00 target price on shares of Enovis in a research note on Monday, October 5th. Zacks Research upgraded shares of Enovis from a "strong sell" rating to a "hold" rating in a research note on Wednesday, July 29th. Citigroup reaffirmed a "market outperform" rating on shares of Enovis in a report on Wednesday, September 2nd. Citizens Jmp cut their price target on Enovis from $55.00 to $47.00 and set a "market outperform" rating on the stock in a report on Wednesday, September 2nd. Finally, Needham & Company LLC boosted their price objective on Enovis from $34.00 to $38.00 and gave the stock a "buy" rating in a research report on Thursday. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.62.

Enovis Stock Performance

Shares of NYSE:ENOV traded down $1.32 during trading on Friday, hitting $27.30. 831,913 shares of the company traded hands, compared to its average volume of 1,267,764. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -1.43 and a beta of 1.31. The business's fifty day moving average is $19.86 and its 200-day moving average is $23.07. Enovis has a one year low of $16.70 and a one year high of $32.41. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.77 by $0.11. The company had revenue of $558.73 million for the quarter, compared to analysts' expectations of $557.12 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The firm's quarterly revenue was up 1.8% compared to the same quarter last year. During the same period last year, the business posted $0.75 earnings per share. As a group, equities analysts predict that Enovis will post 3.15 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Oliver Engert bought 2,660 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The stock was purchased at an average price of $18.80 per share, for a total transaction of $50,008.00. Following the transaction, the insider directly owned 63,898 shares of the company's stock, valued at approximately $1,201,282.40. This represents a 4.34% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Damien Mcdonald bought 13,035 shares of the stock in a transaction on Friday, September 4th. The shares were bought at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the purchase, the chief executive officer owned 247,077 shares in the company, valued at $4,731,524.55. This trade represents a 5.57% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 23,293 shares of company stock valued at $449,599 in the last ninety days. Corporate insiders own 2.90% of the company's stock.

Institutional Investors Weigh In On Enovis

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. IFP Advisors Inc grew its position in Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company's stock valued at $25,000 after purchasing an additional 1,174 shares in the last quarter. Allworth Financial LP acquired a new stake in shares of Enovis during the 2nd quarter worth $36,000. Integrated Wealth Concepts LLC bought a new stake in shares of Enovis during the 2nd quarter worth $39,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Enovis during the 2nd quarter valued at $48,000. Finally, SBI Securities Co. Ltd. acquired a new stake in Enovis in the third quarter valued at $55,000. Institutional investors own 98.45% of the company's stock.

More Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q3 earnings beat estimates: Enovis reported adjusted earnings of $0.88 per share, above the $0.77 consensus and up from $0.75 a year earlier. Revenue of $558.7 million edged past expectations and rose 1.8% year over year. Enovis Q3 2026 results
• Positive Sentiment: Higher outlook and buyback: The company raised its 2026 EPS guidance to $3.58–$3.79 and authorized a $200 million share repurchase program. The higher forecast signals improved earnings expectations; repurchases may also support per-share results. Guidance and buyback announcement
• Positive Sentiment: Analysts lifted price targets: Wells Fargo raised its target to $37 and kept an Overweight rating; Needham raised its target to $38 with a Buy rating, and BTIG raised its target to $42 with a Buy rating. These revisions reflect more optimistic analyst views following the results. Wells Fargo ratings
• Neutral Sentiment: Despite these positive updates, ENOV was lower in the supplied trading snapshot. The available reports do not cite a specific negative development explaining the weakness.

Enovis Company Profile

Enovis Corporation NYSE: ENOV is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company's products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.